Tag: NETTER-1 clinical trial

Lu 177

FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

January 26, 2018

BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors

READ MORE
immunotherapy researchers june hu kunz

10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community

December 18, 2014

As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

READ MORE
jim weiveris

10 Highlights of the Year 2013 for the Carcinoid and Neuroendocrine Tumor Community

December 18, 2013

As the Carcinoid Cancer Foundation looks back on the year 2013, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

READ MORE
excel diagnostics logo 2

Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients

May 15, 2013

For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in  the United States, Excel Diagnostics and Nuclear Oncology Center  in Houston, Texas, in collaboration with…

READ MORE